Leonard Reyno Biography and Net Worth

https://immuneering.com/our-story/leadership/ of C4 Therapeutics

Leonard (Len) Reyno, M.D. joined C4 Therapeutics in July 2023 as our Chief Medical Officer. Previously, he served as President and Chief Medical Officer at Pionyr Immunotherapeutics. Len has close to 30 years of experience in oncology drug development experience, spanning from investigational new drug (IND) applications to Phase IV trials across pharmaceutical, biotech and academic settings. Prior to Pionyr Immunotherapies, Len was Executive Vice President and Chief Medical Officer at ORIC Pharmaceuticals. Previously, he spent a decade at Astellas Pharma in roles of increasing responsibility, most recently as Senior Vice President and Chief Medical Officer, Clinical Research and Development of Agensys, Inc., an affiliate of Astellas. Len has played pivotal roles in several drug approvals and launches, including Herceptin® for Her2+ breast cancer during his tenure at Genentech, Inc. and Taxotere® for the adjuvant treatment of breast cancer while at Aventis and Padcev® in metastatic bladder cancer. Len received his M.D. degree from McMaster University Medical School and a B.Sc. in Chemistry from Dalhousie University.

What is Leonard Reyno's net worth?: The estimated net worth of Leonard Reyno is at least $463.67 thousand as of January 16th, 2026. Dr. Reyno owns 156,382 shares of C4 Therapeutics stock worth more than $463,673 as of May 6th. This net worth estimate does not reflect any other assets that Dr. Reyno may own. Learn More about Leonard Reyno's net worth.
How do I contact Leonard Reyno?: The corporate mailing address for Dr. Reyno and other C4 Therapeutics executives is , , . C4 Therapeutics can also be reached via phone at 617-231-0700 and via email at [email protected]. Learn More on Leonard Reyno's contact information.
Has Leonard Reyno been buying or selling shares of C4 Therapeutics?: Leonard Reyno has not been actively trading shares of C4 Therapeutics during the last ninety days. Most recently, Leonard Reyno sold 10,000 shares of the business's stock in a transaction on Friday, January 16th. The shares were sold at an average price of $2.22, for a transaction totalling $22,200.00. Following the completion of the sale, the insider now directly owns 156,382 shares of the company's stock, valued at $347,168.04. Learn More on Leonard Reyno's trading history.
Who are C4 Therapeutics' active insiders?: C4 Therapeutics' insider roster includes Adam Crystal (Insider), Stewart Fisher (Insider), Elena Prokupets (Director), Leonard Reyno (https://immuneering.com/our-story/leadership/), Malcolm Salter (Director), and Jolie Siegel (Insider). Learn More on C4 Therapeutics' active insiders.
Are insiders buying or selling shares of C4 Therapeutics?: In the last year, insiders at the sold shares 1 times. They sold a total of 10,000 shares worth more than $22,200.00. The most recent insider tranaction occured on January, 16th when insider Leonard Reyno sold 10,000 shares worth more than $22,200.00. Insiders at C4 Therapeutics own 8.7% of the company. Learn More about insider trades at C4 Therapeutics.
Information on this page was last updated on 1/16/2026.

Leonard Reyno Insider Trading History at C4 Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/16/2026	Sell	10,000	$2.22	$22,200.00	156,382

Leonard Reyno Buying and Selling Activity at C4 Therapeutics

C4 Therapeutics Company Overview

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $2.96

$2.90

$3.01

50 Day Range

MA: $2.80

$2.30

$3.59

2 Week Range

Now: $2.96

$1.21

$3.82

Volume

792,798 shs

Average Volume

2,363,431 shs

Market Capitalization

$325.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.77